Drugs / BITS7201A
BITS7201A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02748642 | Apr 2016 → Jun 2017 | asthma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BITS7201A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02748642 ↗ |
| Known as | RG-7990 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297913 ↗ |
| Known as | RO-7040547 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297913 ↗ |
| Action | Inhibit | “BITS7201A is a novel, humanized bispecific antibody that binds and neutralizes both IL-13 and IL-17.” PMID 30616547 ↗ Jan 2019 |
| Modality | Monoclonal antibody | “BITS7201A exhibited single- and multiple-dose pharmacokinetic characteristics consistent with an IgG monoclonal antibody” PMID 30616547 ↗ Jan 2019 |
| Route | Intravenous | “30-, 90-, and 300-mg subcutaneous (SC), and 300- and 750-mg intravenous (IV).” PMID 30616547 ↗ Jan 2019 |
| Route | Subcutaneous | “30-, 90-, and 300-mg subcutaneous (SC), and 300- and 750-mg intravenous (IV).” PMID 30616547 ↗ Jan 2019 |